Syngene is excited to be participating in CPHI Milan, which is by far the largest and most popular pharma event of the year. We are among the preferred contract research development and manufacturing organizations (CRDMOs), successfully delivering integrated, end-to-end drug discovery, development, and manufacturing services across small molecules and biologics.
Having a single partner with a broad suite of capabilities, as opposed to multiple specialty partners, means being able to manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables. By delivering all services from one campus, we enable timely completion of projects, efficiency, and cost savings to clients.
Throughout our 30 years of history, we have worked with over 1000 companies and are currently the preferred partner to 400+ global organizations (15 of the top 20 global biopharma companies are our clients). In terms of innovation, we are co-authors of 400+ patents held with clients. Given our history and experience, we have the capability and experience to design a customized journey to take your molecule from early discovery to commercial manufacturing in the shortest possible time.
The Syngene advantage
Quality focus
We are a fully digitized quality organization with a strong compliance track record with global regulators. Our facilities are US FDA, EMA, and PMDA approved, GLP certified, and AAALAC accredited. In the last financial year, we completed 78 client and regulator audits.
Manufacturing capacity
An API commercial manufacturing capacity of 70,000 L and a biologics commercial manufacturing capacity of 28,000 L (expandable); commercial-scale sterile fill-finish facility with a capacity of 1 million vials per day.
Sustainability
As part of our commitment to sustainability, we recycled 38% water, consumed 75% renewable energy, and recycled 90.75% waste. We also had zero environmental violations.
Green chemistry innovation
Implemented green chemistry across process design, process development, execution, and disposal phases. Also, reduced raw materials, solvents, waste, and disposal.
Flexible business models
Offering various business models such as dedicated R&D labs (for long-term partnerships), fee-for-service, full-time equivalent, and risk-reward models (milestone-based).
Robust supply chain
A network of 2500+ suppliers across 30+ countries, contracts with global partners, 24X7 local arrangements, and extended support to local partners.Meet our experts
Jonathan Hunt
Managing Director and Chief Executive Officer
Ian Grundy
Head of Sales, Development and Manufacturing
Sudhir Nambiar
Head of CMC, Small Molecules
Jeff Wong
Head of Sales, Biologics
Sumanth Prabhu
Head of Analytical Services, Small Molecules
Manoj Babu
VP Sales, Development & Manufacturing Services
Yogesh Shinde
Business Development, Small Molecules - Contract Manufacturing
Vivek Kumaravel
Business development, Formulation Services
Satish Pattamsetty
Business development, Analytical Services
Rahul Dwivedi
Sr. Director - Business Development, Human Pharmacology Unit
Our services
Small Molecule Development and Manufacturing
Syngene offers chemical development, formulation, analytical, clinical development, and manufacturing services across small molecules, oligonucleotides, HPAPIs, and performance and specialty materials.
Biologics Development and Manufacturing
Syngene offers biologics development and manufacturing solutions for both mammalian and microbial systems. We also offer services from our sterile Fill-Finish facility and Viral Testing facility.
Clinical Development
Syngene offers BA/BE studies for generic drugs, clinical trial management (Phase1-3), central laboratory services, regulated bioanalytical lab services, clinical data management, and biometric services.
Animal Health
Syngene offers comprehensive Animal Healthcare services across the drug discovery, development, and manufacturing continuum for small molecules and biologics.
Syngene International Limited. All rights reserved © 2024